Treatment planning in the field of radiation therapy has evolved from three-dimensional (3D) planning to inverse planning and, most recently, to personalized adaptive radiotherapy (ART)
15 July 2025 in Journal of Applied Clinical Medical Physics
Purpose: To evaluate the feasibility of translating clinical lung stereotactic ablative radiotherapy (SAbR) templates from Ethos1.1 to Ethos2.0, leveraging new features to facilitate dose fall‐off and automate patient‐specific beam arrangement. This study aims to streamline planning processes and support broader adoption of online adaptive radiotherapy (ART) for lung SAbR. Methods: We selected fifteen patients previously treated with adaptive lung SAbR using the Ethos1.1 system, each receiving 40–60 Gy in 5 fractions. Plans were reoptimized in Ethos2.0 using identical parameters (rIMRT) to their clinical counterpart. To evaluate new integrated features, we utilized high‐fidelity (HF) mode with and without automatic treatment geometry selection (HF‐cIMRT, HF‐aIMRT/VMAT). These strategies were compared to assess the impact of Ethos2.0's new features on plan quality and efficiency using RTOG‐based metrics and enhanced plan deliverability analysis. Statistical significance was assessed using paired Student's t ‐tests ( α = 0.05). Results: All plans reoptimized in Ethos2.0 demonstrated acceptable plan quality. No statistically significant differences in maximum organ‐at‐risk doses were observed between evaluated strategies and the clinical plan. For complex cases, human‐selected beam geometry proved superior to automated geometry. HF‐enabled plans significantly reduced total monitor units, with HF‐aVMAT, HF‐cIMRT, and HF‐aIMRT reporting 3142.4 ± 997.4 ( p < 0.001), 3401.8 ± 516.1 ( p < 0.001), and 3225.6 ± 484.2 ( p < 0.001) compared to clinical 5424.9 ± 1353.4. A trade‐off was observed in conformity index, which was 1.06 ± 0.08 ( p = 0.006), 1.05 ± 0.06 ( p = 0.003), and 1.03 ± 0.05 ( p = 0.05) for HF‐aIMRT, HF‐cIMRT, and HF‐aVMAT plans compared to clinical 1.01 ± 0.03. Conclusion: Lung SAbR planning strategies can be effectively transitioned from Ethos1.1 to Ethos2.0, improving workflow efficiency with high‐fidelity mode and minor adjustments. Automated beam geometry tools enhance planner efficiency for both IMRT and VMAT. To address increased ART workload and staffing demands, leveraging integrated automation tools is essential. The planning strategies presented in this study are straightforward and reproducible for ART‐enabled clinics.
Background/Objectives: Patients with early-stage non-small cell lung cancer (NSCLC) or limited lung metastases and compromised lung function, such as those with interstitial lung disease (ILD) or chronic obstructive pulmonary disease (COPD), or other factors rendering them high-risk for surgery or medically inoperable, face increased risks of treatment-related toxicity from stereotactic ablative radiation therapy (SABR). This study evaluated a novel treatment approach to mitigate these risks. Methods: We investigated Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR), delivered as pulsed radiation every three weeks, in patients with <5 cm lung tumors and ILD, COPD, or prior therapy. Treatment occurred between 2022 and 2024. Online adaptive radiotherapy (o-ART) was employed in 20 patients (80%) to modify treatment plans when anatomical changes warranted replanning. Primary outcomes included volumetric tumor response, changes in dose to organs at risk (OARs) and acute events, while secondary outcomes included local and tumor control, and overall survival. Results: Twenty-three patients received PULSAR treatment at doses between 40 Gy and 60 Gy in 5 fractions and one patient received 54 Gy in 3 fractions, with a median follow-up time of 16.2 months. Approximately half of treated patients demonstrated volumetric tumor response, with median residual volume of 70% (range 36–100%) at maximal response. Among the 20 patients (80%) who underwent online adaptive replanning, significant reductions in OAR dosimetry were observed for all organs assessed including the Dmax for heart (p = 0.0053), bronchus (p = 0.0003), esophagus (p = 0.0005), spinal cord (p = 0.025), and the lung V20 Gy and V12.5 Gy (p < 0.0001). Treatment-related toxicity included two grade 1–2 adverse events and six grade 3 events consisting of pneumonitis, dyspnea or lung infection, with no grade 4 or 5 events. Median progression-free survival was 21.1 months, with 1-year overall survival of 74% and 1-year local control of 100%. Conclusions: PULSAR shows promise as a feasible treatment option for high-risk patients with NSCLC or lung metastases, demonstrating no grade 5 events and complete tumor control. Additional research is needed to fully evaluate the safety profile of PULSAR in the high-risk subgroups and whether PULSAR’s treatment intervals and adaptive planning advantages lead to improved long-term outcomes compared to conventional, uninterrupted SABR regimens.
3 December 2024 in Journal of Applied Clinical Medical Physics
Purpose: Optimal head‐and‐neck cancer (HNC) treatment planning requires accurate and feasible planning goals to meet dosimetric constraints and generate robust online adaptive treatment plans. A new x‐ray‐based adaptive radiotherapy (ART) treatment planning system (TPS) version 2.0 emulator includes novel methods to drive the planning process including the revised intelligent optimization engine algorithm (IOE2). HNC is among the most challenging and complex sites and heavily depends on planner skill and experience to successfully generate a reference plan. Therefore, we evaluate the new TPS performance via conventionally accepted planning strategies with/without artificial intelligence (AI) and knowledge‐based planning (KBP).Methods: Our institution has a pre‐clinical release of the Varian Ethos2.0 TPS emulator which includes several changes that may affect current planning strategies. Twenty definitive and post‐operative HNC patients were retrospectively selected with a two or three‐level simultaneous integrated boost (SIB) dosing scheme. Patients were replanned in the emulator using population‐based, KBP‐guided with/without human intervention and AI‐guided planning goals. These planning strategies were compared both dosimetrically and for plan deliverability.Results: All strategies generally demonstrated acceptable plan quality with KBP‐ and AI‐guided goals offering enhanced dosimetric sparing in organs‐at‐risk (OAR). The average contralateral parotid gland mean dose was 20.0 ± 6.1 Gy (p < 0.001) for population‐based and 15.0 ± 6.1 Gy (p = n.s.) for KBP‐with human intervention versus 15.1 ± 7.4 Gy for clinical plans. Target coverage, minimum dose, and plan hotspot were acceptable in all cases. KBP‐enabled strategy demonstrated higher modulation and faster optimization time than both population‐based and AI‐guided strategies.Conclusion: Simply entering population, automatic KBP‐enabled or AI‐generated planning goals into the new Ethos2.0 TPS produced dosimetrically compliant plans, with AI‐guided goals demonstrating the most OAR sparing. Several of these approaches are easy to translate to other treatment sites and will help lower the barrier to entry for x‐ray‐based online‐ART.